| P2093 | author name string | Yuan C | |
| | Song G | |
| | Jiang G | |
| P2860 | cites work | [Induction of anti-leukemic immunity of dendritic cells derived from multidrug resistant leukemia K562/A02 cells with high expression of P-glycoprotein and sensitive K562 cells] | Q82221325 |
| | Induction of leukemic-cell-specific cytotoxic T lymphocytes by autologous monocyte-derived dendritic cells presenting leukemic cell antigens | Q82997735 |
| | Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia | Q83149273 |
| | Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia | Q28178372 |
| | Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia | Q28201442 |
| | Establishment and characterization of a human histiocytic lymphoma cell line (U-937) | Q29619570 |
| | Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo | Q30080006 |
| | Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution | Q33180586 |
| | [The induction of differentiation into dendritic cells from HL-60 cells by calcium ionophore]. | Q33203947 |
| | A cell line model for the differentiation of human dendritic cells | Q33217350 |
| | [Research on A23187 inducing HL-60 cells to differentiate into dendritic cells]. | Q33282346 |
| | Immunotherapy in acute leukemia | Q33731552 |
| | Malignant counterpart of myeloid dendritic cell (DC) belonging to acute myelogenous leukemia (AML) exhibits a dichotomous immunoregulatory potential | Q34170214 |
| | Dendritic cells as vectors for therapy | Q34339199 |
| | Therapeutic potential of leukemia-derived dendritic cells: preclinical and clinical progress | Q34408287 |
| | Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia | Q34412762 |
| | Leukemic dendritic cells: potential for therapy and insights towards immune escape by leukemic blasts | Q34980036 |
| | Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells | Q35620629 |
| | Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells | Q73595155 |
| | Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells | Q73607376 |
| | Identification of CD14 as a predictor for leukemic dendritic cell differentiation in acute myeloid leukemia | Q73720258 |
| | In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo cell therapy | Q73797746 |
| | Wilms tumor gene (wt1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors | Q73838850 |
| | Maturation of dendritic cells by recombinant human CD40L-trimer leads to a homogeneous cell population with enhanced surface marker expression and increased cytokine production | Q74083639 |
| | Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia | Q74106181 |
| | Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions | Q74179201 |
| | Generation of dendritic cells from human chronic myelomonocytic leukemia cells in fetal calf serum-free medium | Q74210485 |
| | Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study | Q74632747 |
| | Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses | Q77911843 |
| | Calcium mobilization in human myeloid cells results in acquisition of individual dendritic cell-like characteristics through discrete signaling pathways | Q77929119 |
| | Calcium ionophore-treated myeloid cells acquire many dendritic cell characteristics independent of prior differentiation state, transformation status, or sensitivity to biologic agents | Q78102320 |
| | Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias | Q78162686 |
| | Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting | Q79434266 |
| | Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML | Q79774007 |
| | Leukaemic dendritic cell vaccination for patients with acute myeloid leukaemia | Q79843350 |
| | Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy | Q80519181 |
| | Leukemia-derived dendritic cells in acute myeloid leukemia exhibit potent migratory capacity | Q81739628 |
| | Dendritic cell immunotherapy: mapping the way. | Q35762464 |
| | Dendritic-cell-based therapeutic vaccination against cancer | Q36070700 |
| | T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up! | Q36087036 |
| | Employing the immunological synapse in AML: development of leukemic dendritic cells for active specific immunization | Q36257874 |
| | Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethylsulfoxide | Q36341387 |
| | Eosinophilic differentiation of the human promyelocytic leukemia cell line, HL-60 | Q36349240 |
| | Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells | Q36369028 |
| | Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid | Q36390529 |
| | Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia. | Q36419010 |
| | Human dendritic cell line models for DC differentiation and clinical DC vaccination studies | Q37229552 |
| | Human promyelocytic leukemia cells in culture differentiate into macrophage-like cells when treated with a phorbol diester | Q37333253 |
| | Transcriptional IL-15-directed in vivo DC targeting DNA vaccine | Q37388709 |
| | Review of human DC subtypes | Q37639217 |
| | The evolving role of dendritic cells in cancer therapy | Q37687418 |
| | Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia | Q38294373 |
| | Transcriptional and functional defects of dendritic cells derived from the MUTZ-3 leukaemia line | Q38509836 |
| | Induction of JAM-A during differentiation of human THP-1 dendritic cells | Q39800453 |
| | MUTZ-3-derived dendritic cells as an in vitro alternative model to CD34+ progenitor-derived dendritic cells for testing of chemical sensitizers. | Q39803285 |
| | Ganoderma lucidum polysaccharides can induce human monocytic leukemia cells into dendritic cells with immuno-stimulatory function. | Q39958901 |
| | Inducing antitumor T cell immunity: comparative functional analysis of interstitial versus Langerhans dendritic cells in a human cell line model. | Q40000399 |
| | Phenotypic and functional differentiation of KG-1 into dendritic-like cells. | Q40022631 |
| | A CD34(+) human cell line model of myeloid dendritic cell differentiation: evidence for a CD14(+)CD11b(+) Langerhans cell precursor | Q40234386 |
| | Phosphatidic acid induces the differentiation of human acute promyelocytic leukemic cells into dendritic cell-like | Q40240953 |
| | Impaired responses of leukemic dendritic cells derived from a human myeloid cell line to LPS stimulation | Q40308044 |
| | Functional and transcriptional profiling of MUTZ-3, a myeloid cell line acting as a model for dendritic cells | Q40327786 |
| | Expression of poliovirus receptor-related proteins PRR1 and PRR2 in acute myeloid leukemia: first report of surface marker analysis, contribution to diagnosis, prognosis and implications for future therapeutical strategies | Q40369527 |
| | Effects of cyclophilin A on myeloblastic cell line KG-1 derived dendritic like cells (DLC) through p38 MAP kinase activation | Q40407769 |
| | Differential expression of dendritic cell markers by all-trans retinoic acid on human acute promyelocytic leukemic cell line | Q40509919 |
| | New phenotypic, functional and electrophysiological characteristics of KG-1 cells. | Q40567380 |
| | Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer | Q40572007 |
| | Tumor necrosis factor alpha-stimulated endothelium: an inducer of dendritic cell development from hematopoietic progenitors and myeloid leukemic cells | Q40584474 |
| | Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia | Q40662452 |
| | Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells | Q40701084 |
| | Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination | Q40719320 |
| | Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation | Q40912559 |
| | CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens. | Q41013721 |
| | Dendritic cells: unique leukocyte populations which control the primary immune response | Q41621775 |
| | CD40 triggering increases the efficiency of dendritic cells for antitumoral immunization | Q42801802 |
| | Establishment and characterization of two novel cytokine-responsive acute myeloid and monocytic leukemia cell lines, MUTZ-2 and MUTZ-3. | Q42811671 |
| | Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells | Q42944333 |
| | Immunological evaluation for CML and its possibility for an immunotherapy | Q43282781 |
| | Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes | Q43501678 |
| | Lymphocytes from multi-transfused patients exhibit cytotoxicity against autologous cells | Q43707286 |
| | Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL. | Q44539431 |
| | Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia | Q44888626 |
| | Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation | Q44993179 |
| | Large-scale generation of autologous dendritic cells for immunotherapy in patients with acute myeloid leukemia | Q45789544 |
| | Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. | Q45863355 |
| | Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells. | Q45876960 |
| | Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods. | Q45923846 |
| | Histone deacetylase inhibition improves differentiation of dendritic cells from leukemic blasts of patients with TEL/AML1-positive acute lymphoblastic leukemia | Q46171835 |
| | The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells | Q46639402 |
| | The biological characteristics of dendritic cells derived in vitro from myelogeneous leukemia cells and healthy donor cells | Q46800684 |
| | Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts | Q46981736 |
| | Induction of chronic lymphocytic leukemia (CLL)–specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells | Q47387344 |
| | TNF-alpha receptor 1 expression on acute myeloid leukemic blasts predicts differentiation into leukemic dendritic cells | Q47761727 |
| | Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma | Q47975518 |
| | Transduction with a fiber-modified adenoviral vector is superior to non-viral nucleofection for expressing tumor-associated Ag mucin-1 in human DC. | Q50732963 |
| | The first 1000 dendritic cell vaccinees. | Q50736412 |
| | The expression of co-stimulatory molecules and their relationship to the prognosis of human acute myeloid leukaemia: poor prognosis of B7-2-positive leukaemia. | Q50864825 |
| | Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). | Q50939176 |
| | Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential. | Q51043270 |
| | T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC). | Q51326091 |
| | Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes. | Q51522503 |
| | Presentation of tumor antigens by phagocytic dendritic cell clusters generated from human CD34+ hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia patients. | Q52534940 |
| | Bcr/abl+ autologous dendritic cells for vaccination in chronic myeloid leukemia. | Q52970484 |
| | Down-regulation of cellular vascular endothelial growth factor levels induces differentiation of leukemic cells to functional leukemic-dendritic cells in acute myeloid leukemia. | Q53585655 |
| | Modulation of tumor necrosis factor (TNF) receptor expression during monocytic differentiation by glucocorticoids. | Q53981432 |
| | [Immunotherapy and cell therapy for myeloid leukemia]. | Q54713014 |
| | Divergent autologous T cell responses to leukaemic dendritic cells during remission in acute promyelocytic leukaemia. | Q54924332 |
| | CD28/CTLA-4 ligands: the gene encoding CD86 (B70/B7.2) maps to the same region as CD80 (B7/B7.1) gene in human chromosome 3q13-q23 | Q56909457 |
| | Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state | Q57779701 |
| | Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients | Q58619964 |
| | Thymic dendritic cells and T cells develop simultaneously in the thymus from a common precursor population | Q59056890 |
| | Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients | Q64380078 |
| | 1 alpha,25-Dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cells | Q72025020 |
| | Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia | Q73063879 |
| | Effect of costimulation and the microenvironment on antigen presentation by leukemic cells | Q73160423 |
| | Dendritic cell vaccination for patients with chronic myelogenous leukemia | Q73520063 |
| | In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice | Q73549844 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| | dendritic cell | Q506253 |
| | immunotherapy | Q1427096 |
| P304 | page(s) | 53-65 | |
| P577 | publication date | 2012-05-01 | |
| P1433 | published in | Intractable & Rare Diseases Research | Q26841793 |
| P1476 | title | The characterization and role of leukemia cell-derived dendritic cells in immunotherapy for leukemic diseases | |
| P478 | volume | 1 | |